AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03540134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracerebral Infusion of Autologous Cerebral Spinal Fluid
Description: Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
Study NCT00633581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C)
Description: Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
Study NCT00633581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single intravenous injection of 120ml of normal saline over 30 minutes
Study NCT04671316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5209 60mg Tab
Description: single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water
Study NCT04671316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5209 60mg Tab
Description: single oral administration of 1 tablet of DA-5209 60mg Tab without water
Study NCT02340195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine (Lu AE58054) 60 mg
Description: encapsulated film-coated tablets for oral use once daily for 10 days
Study NCT01832506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2156119J
Description: Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
Study NCT01014871 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum Toxin Type A - Azzalure
Description: One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
Study NCT01014871 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum Toxin Type A - Vistabel
Description: One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
Study NCT04671316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixiana 60mg Tab
Description: single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water
Study NCT01887028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher and Paykel Humidifier (MR860AEU)
Description: Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
Study NCT01887028 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fisher and Paykel Humidifier (MR860AEU)
Description: Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
Study NCT03916250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 cream
Description: PF-06700841 will be applied topically
Study NCT03916250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: White petrolatum
Description: White petrolatum will be applied topically
Study NCT00906074 — intervention group
Intervention type: PROCEDURE
Intervention: Elective or emergency abdominal surgery
Description: Clinical record review.
Study NCT00906074 — intervention group
Intervention type: PROCEDURE
Intervention: Elective or emergency abdominal surgery
Description: Clinical record review
Study NCT04524286 — intervention group
Intervention type: OTHER
Intervention: Interviews only.
Description: Interviews will be conducted with childbearing women and midwives.
Study NCT02471664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Loop Cerclage Annuloplasty
Study NCT03233412 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: Exertion of the cervix transformation zone
Study NCT03233412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Exertion of the cervix transformation zone
Study NCT03233412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
Study NCT00104494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc acetate (20mg/d)
Description: Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
Study NCT04200105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-TBNA
Description: Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle
Study NCT04200105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquire TBNB
Description: Mediastinal and hilar lymph node sampling using the Acquire TBNB needle
Study NCT03670641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
Study NCT03103971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes
Description: Given IV
Study NCT03670641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
Study NCT03670641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
Study NCT03122028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAA closure system
Description: Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
Study NCT03979105 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
Study NCT01176097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5658
Description: oral suspension, escalating single doses
Study NCT02146378 — intervention group
Intervention type: DRUG
Intervention: Vyndaqel
Description: 20mg/day
Study NCT02630641 — intervention group
Intervention type: DRUG
Intervention: Gonadotropin-releasing Hormone (GnRH) agonist therapy
Description: This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
Study NCT04179344 — intervention group
Intervention type: OTHER
Intervention: Integrated e-healthcare services (IeHS) web-based app
Description: Each participant is asked to complete study tasks using the IeHS web-based app as a part of IeHS simulation. This activity is followed by user experience survey, and an in-depth interview to explore user satisfaction on the IeHS web-based app
Study NCT01176097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension,single doses
Study NCT03201172 — intervention group
Intervention type: DEVICE
Intervention: Primary Unicompartmental Knee Arthroplasty
Description: Primary implantation of an unicompartmental knee implant
Study NCT02198924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib and Celecoxib
Description: Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
Study NCT02198924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: control patients are supplied with the corresponding placebo with the same instructions.
Study NCT01711749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor®
Description: Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
Study NCT01711749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin calcium tablets
Description: Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
Study NCT02956616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
Study NCT02956616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
Study NCT02956616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
Study NCT02956616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Protocol
Description: enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
Study NCT02266394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cell
Description: Intra-arterial infusion of the single-dose MSC
Study NCT02266394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cell delivery with stent placement
Description: Intra-arterial stent placement after Mesenchymal stem cell infusion
Study NCT00380549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood ion levels
Description: Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
Study NCT04056052 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mind the Gap: Home Activity Only
Description: The primary focus of the home activity program was based on collaborative parent-child cooking activities which the families undertook themselves at home. There were two key tasks: the first was to add one extra vegetable to the evening meal each day, the second was to select, prepare and cook one recipe from the cook book each week.
Study NCT04056052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind the Gap: Home Activity + cooking Workshop
Description: The main purpose of these workshops was to provide hands-on successful food preparation and cooking experiences for the families and several opportunities to taste new vegetable-based recipes as well as promoting knowledge of cost and healthy eating. Children and their parents were then encouraged to take whatever was learned and apply it at home.
Study NCT00518622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK7009
Description: Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
Study NCT01202162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Administratino of Desflurane
Study NCT01202162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Sevoflurane
Description: Administration of Sevoflurane
Study NCT03822611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Subsidy
Description: Voucher
Study NCT00518622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: MK7009 Placebo
Study NCT02459717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotic
Description: Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
Study NCT02459717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
Study NCT01941108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation Arm
Description: Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
Study NCT01688726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® BALANCE eyedrops
Study NCT01688726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minims® Saline 0.9% eyedrops
Study NCT02923414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard escalating shocks
Description: 125 J, 150 J, 200 J
Study NCT02923414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High energy shock protocol
Description: 360 J, 360 J, 360 J.
Study NCT00871949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 100 mg oral suspension given once
Study NCT02613078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gut-Directed Hypnotherapy
Description: Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
Study NCT02613078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10\^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
Study NCT02613078 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Monitoring
Description: Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
Study NCT02613078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Monitoring
Description: Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
Study NCT03429140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gel-One
Description: an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
Study NCT03429140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
Study NCT01038323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT and milnacipran
Description: Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study.
Study NCT01038323 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT with a placebo
Description: Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study.
Study NCT01038323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Educational with milnacipran
Description: Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study.
Study NCT03705949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate 0.1% drops
Description: Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
Study NCT03705949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate 0.2% drops
Description: Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
Study NCT00871949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 300 mg oral suspension given once
Study NCT00871949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match oral suspension given once
Study NCT00871949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 35 mg oral suspension given once
Study NCT00871949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 1000 mg oral suspension given once
Study NCT00871949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 1500 mg oral suspension given once
Study NCT00871949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: Fed conditions, 600 mg oral suspension given once
Study NCT00871949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 600 mg oral suspension given once
Study NCT04190264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Rehabilitation Machine
Description: The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
Study NCT04190264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Water Immersion
Description: Whole-body immersion in cold water.
Study NCT04787770 — intervention group
Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention
Study NCT03103971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03103971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT00047034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT01771315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
Study NCT03103971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03103971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT03103971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02248480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally
Study NCT02248480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT00920881 — intervention group
Intervention type: DEVICE
Intervention: FreeStyle Navigator Continuous Glucose Monitoring System
Description: Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.